Cargando…
Ventricular tachycardia as presenting arrhythmia as a determinant of appropriate implantable cardioverter-defibrillator therapy in secondary prevention
FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Sudden cardiac death (SCD) is a leading cause of death. The implantable cardioverter-defibrillator (ICD) is an established therapy to prevent SCD in patients with prior ventricular tachycardia (VT) or ventricular fibrillation (VF)....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207291/ http://dx.doi.org/10.1093/europace/euad122.413 |
Sumario: | FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Sudden cardiac death (SCD) is a leading cause of death. The implantable cardioverter-defibrillator (ICD) is an established therapy to prevent SCD in patients with prior ventricular tachycardia (VT) or ventricular fibrillation (VF). Determination of patient characteristics related to ICD therapies may provide targets for more intensive monitoring or management of ventricular arrhythmias. Therefore, we aimed to find determinants of appropriate ICD therapy. METHODS: In this retrospective, single-centre study, 223 consecutive secondary prevention ICD recipients were included. Data was obtained on medical history, laboratory measurements, electrocardiography and echocardiography. The primary outcome was appropriate ICD therapy, which included shock and antitachycardia pacing (ATP) given for VF or VT. Backward stepwise Cox regression analysis was performed to find determinants of appropriate therapy. RESULTS: The median age of the study population was 65.3 years (interquartile range (IQR) 55.4 – 72.0 years). 188 (84.3%) patients were male. 153 (68.6%) patients had ischemic heart disease. During a median follow-up duration of 6.00 years (interquartile range (IQR) 4.85 – 7.70 years), appropriate ICD therapy occurred in 89 (39.9%) patients, appropriate ICD shock in 65 (29.1%) patients, death in 55 (24.7%), inappropriate shock in 11 (4.9%) and device-related complications in 18 (8.1%). VT as index arrhythmia, QRS fragmentation and diminished right ventricular function were determinants of appropriate device therapy. Interestingly, whereas the majority of patients (141 (63.2%)) had an ICD implanted for initial presentation with VF, the first occurrence of appropriate therapy during follow-up was for monomorphic VT in the majority of patients (84 (94.4%)). CONCLUSION: In patients with a secondary prevention ICD indication, VT as presenting arrhythmia is a determinant of appropriate ICD therapy during follow-up. Most ICD therapies during follow-up were applied for monomorphic VT. [Figure: see text] |
---|